Haydn T. Kissick

Haydn T. Kissick

Auto-generated profile, based on publicly available information

Haydn T. Kissick

Emory Vaccine Center, Emory University School of Medicine, Atlanta, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2019 in Nature
Verified
Journal Article
Closed access
PDF file
CJCaroline S. Jansen
Caroline S. Jansen
NPNataliya Prokhnevska
Nataliya Prokhnevska
VMViraj A. Master
Viraj A. Master
MSMartin G. Sanda
Martin G. Sanda
JCJennifer W. Carlisle
Jennifer W. Carlisle
HKHaydn Kissick
Haydn Kissick

29 January 2018 in Annual Review of Medicine
Verified
Journal Article
Closed access
MHMasao Hashimoto
Masao Hashimoto
AKAlice O. Kamphorst
Alice O. Kamphorst
SISe Jin Im
Se Jin Im
HKHaydn T. Kissick
Haydn T. Kissick
RPRathi N. Pillai
Rathi N. Pillai
RARafi Ahmed
Rafi Ahmed
Antigen-specific CD8 T cells are central to the control of chronic infections and cancer, but persistent antigen stimulation results in T cell exhaustion. Exhausted CD8 T cells have decreased effector function and proliferative capacity, partly caused by overexpression of inhibitory receptors such as programmed cell death (PD)-1. Blockade of the PD-1 pathway has opened a new therapeutic avenue for reinvigorating T cell responses, with positive outcomes especially for patients with cancer. Other strategies to restore function in exhausted CD8 T cells are currently under evaluation—many in combination with PD-1-targeted therapy. Exhausted CD8 T cells comprise heterogeneous cell populations with unique differentiation and functional states. A subset of stem cell–like PD-1+ CD8 T cells responsible for the proliferative burst after PD-1 therapy has been recently described. A greater understanding of T cell exhaustion is imperative to establish rational immunotherapeutic interventions.

28 December 2022 in Immunity
Verified
Journal Article
Closed access
NPNataliya Prokhnevska
Nataliya Prokhnevska
MCMaria A. Cardenas
Maria A. Cardenas
RVRajesh M. Valanparambil
Rajesh M. Valanparambil
ESEwelina Sobierajska
Ewelina Sobierajska
BBBenjamin G. Barwick
Benjamin G. Barwick
HKHaydn Kissick
Haydn Kissick

28 September 2022 in Nature
Verified
Journal Article
Closed access
PDF file
MHMasao Hashimoto
Masao Hashimoto
KAKoichi Araki
Koichi Araki
MCMaria A. Cardenas
Maria A. Cardenas
PLPeng Li
Peng Li
RJRohit Jadhav
Rohit Jadhav
RARafi Ahmed
Rafi Ahmed

1 September 2021 in Nature
Verified
Journal Article
Closed access
PDF file
CEChristiane S. Eberhardt
Christiane S. Eberhardt
HKHaydn T. Kissick
Haydn T. Kissick
MPMihir R. Patel
Mihir R. Patel
MCMaria A. Cardenas
Maria A. Cardenas
NPNataliya Prokhnevska
Nataliya Prokhnevska
RARafi Ahmed
Rafi Ahmed

28 September 2022 in Nature
Verified
Journal Article
Open access
PDF file
LDLaura Codarri Deak
Laura Codarri Deak
VNValeria Nicolini
Valeria Nicolini
MHMasao Hashimoto
Masao Hashimoto
MKMaria Karagianni
Maria Karagianni
PSPetra C. Schwalie
Petra C. Schwalie
PUPablo Umaña
Pablo Umaña
Expansion and differentiation of antigen-experienced PD-1+TCF-1+ stem-like CD8+ T cells into effector cells is critical for the success of immunotherapies based on PD-1 blockade1–4. Hashimoto et al. have shown that, in chronic infections, administration of the cytokine interleukin (IL)-2 triggers an alternative differentiation path of stem-like T cells towards a distinct population of ‘better effector’ CD8+ T cells similar to those generated in an acute infection5. IL-2 binding to the IL-2 receptor α-chain (CD25) was essential in triggering this alternative differentiation path and expanding better effectors with distinct transcriptional and epigenetic profiles. However, constitutive expression of CD25 on regulatory T cells and some endothelial cells also contributes to unwanted systemic effects from IL-2 therapy. Therefore, engineered IL-2 receptor β- and γ-chain (IL-2Rβγ)-biased agonists are currently being developed6–10. Here we show that IL-2Rβγ-biased agonists are unable to preferentially expand better effector T cells in cancer models and describe PD1-IL2v, a new immunocytokine that overcomes the need for CD25 binding by docking in cis to PD-1. Cis binding of PD1-IL2v to PD-1 and IL-2Rβγ on the same cell recovers the ability to differentiate stem-like CD8+ T cells into better effectors in the absence of CD25 binding in both chronic infection and cancer models and provides superior efficacy. By contrast, PD-1- or PD-L1-blocking antibodies alone, or their combination with clinically relevant doses of non-PD-1-targeted IL2v, cannot expand this unique subset of better effector T cells and instead lead to the accumulation of terminally differentiated, exhausted T cells. These findings provide the basis for the development of a new generation of PD-1 cis-targeted IL-2R agonists with enhanced therapeutic potential for the treatment of cancer and chronic infections.